My Application Form Status

Check the status of your application form with Angel Broking.
  • Companies
  • Everything else
Search

Sanofi India Ltd Research Report - 06th May 2016

Pharmaceutical | Published on May 06th 2016

IT

Sanofi India (Sanofi)’s 1QCY2016 results have come in lower than our expectation; the company posted a 10.1% yoy growth in revenue to Rs506cr V/s an expected Rs593cr. On the operating front, the gross margin came in at 52.1%, almost in line with our expectation, and V/s 47.8% in the corresponding period of last year. The OPM came in at 18.0% V/s an expected 20.0% and V/s 11.7% in the corresponding period of last year. Consequently, the PAT came in at Rs81cr (V/s an expected Rs88cr), a yoy growth of 67.9%. We recommend an Accumulate rating on the stock. Lower-than-expected results: The company posted a 10.1% yoy growth in revenue to Rs506cr (V/s an expected Rs593cr). We expect revenue growth to sustain in the coming quarters with improvement in volumes along with likely price hikes in DPCO products. On the operating front, the gross margin came in at 52.1%, almost in line with our expectation, and V/s 47.8% in the corresponding period of last year. The OPM came in at 18.0% V/s an expected 20.0% and V/s 11.7% in the corresponding period of last year. Consequently, the PAT came in at Rs81cr (V/s an expected Rs88cr), a yoy growth of 67.9%. Tax as % of PBT was 35.3% V/s 26.5% in 1QCY2015. Other income for the quarter grew 30.0% yoy to Rs64cr. Outlook and valuation: We expect net sales to post a 14.6% CAGR to Rs2,692cr and EPS to register a 21.2% CAGR to `169.2 over CY2015–17E. At current levels, the stock is trading at 28.7x and 26.1x its CY2016E and CY2017E earnings, respectively. Given the valuations, we recommend an Accumulate rating on the stock.

Download Full Report

Accumulate

CMP 4,410
Target Price 4,738
Investment Period12 Months

Stock Info

MCAP BSE (Rs in Cr)9,797.42
MCAP NSE (Rs in Cr)9,753.90
P/E (x)30.91
EPS (Rs.)137.62
BV (Rs.)756.74
Div Yield (%)1.53
FV (Rs.)10.00
P/BV (x)5.62
EV/Sales (x)4.21
EV/EBITDA (x)18.61

Shareholding Pattern (%)

Promoter60.0
Foreign15.0
Institution15.0
Public & Others6.0
Corporate4.0
Grand Total100.0

Trade Securely

AngelEye

Portfolio Tracking & Trading Application View Demo